drugset / Trial / NCT00117780

Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes

NCT00117780

Phase 4 Completed 520 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this research study is to compare the efficacy (reduction in HbA1c and in blood glucose levels) of insulin detemir once daily injection compared to insulin detemir twice daily injection administered as basal insulin for the treatment of type 1 diabetes and to verify the safety of use (number and severity of episodes of hypoglycemia, body weight and side effects).

Timeline

Start
2005-06
Primary completion
2006-10
Completion
2006-10

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin detemir Protein / enzyme biologic 29 iu Other
Subject insulin detemir Protein / enzyme biologic 39 iu Other
Background insulin aspart Protein / enzyme biologic 26 iu
Background insulin aspart Protein / enzyme biologic 34 iu